Vaccination

Vaccination is the best protection

Today, vaccines like Menveo® offer the best way to help prevent meningococcal disease, including meningococcal meningitis.1

In some regions, like Africa’s “meningitis belt,” sudden outbreaks make the need for vaccination clear. In other areas such as the United States, where meningococcal meningitis is rare, people don’t realize the importance of immunization.

So many people at risk, so few vaccinated

The Centers for Disease Control and Prevention (CDC) recommends vaccination for children 11 through 18 years of age, along with vaccinations for adults also at risk.2 In 2007, however, just under 33% of all teens between 13 and 17 years old received a recommended vaccine.3

Meningococcal disease may not be common in the United States, but that doesn’t make it any less dangerous for those who get it. Getting your child vaccinated helps protect him or her from the terrible consequences of this deadly disease.1

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

References

  1. Meningitis: Prevention. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/about/prevention.html. Accessed March 3, 2010.
  2. Meningitis: Meningococcal vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/vaccine-info.html. Accessed March 3, 2010.
  3. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13–17 years—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:1100–1103. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5740a2.htm?s_cid=mm5740a2_e. Accessed March 3, 2010.
  4. Vaccines & immunizations. How vaccines prevent disease. Centers for Disease Control and Prevention Web site. http://cdc.gov/vaccines/vac-gen/howvpd.htm. Accessed March 3, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel